| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcal Infections | 25 | 2022 | 248 | 5.360 |
Why?
|
| Streptococcus agalactiae | 27 | 2022 | 103 | 4.530 |
Why?
|
| Chagas Disease | 7 | 2023 | 309 | 2.570 |
Why?
|
| Infectious Disease Transmission, Vertical | 10 | 2023 | 253 | 2.530 |
Why?
|
| Streptococcal Vaccines | 12 | 2019 | 18 | 1.890 |
Why?
|
| Intraabdominal Infections | 8 | 2024 | 19 | 1.780 |
Why?
|
| Pregnancy Complications, Parasitic | 3 | 2021 | 27 | 1.760 |
Why?
|
| Trypanosoma cruzi | 5 | 2021 | 251 | 1.660 |
Why?
|
| Pregnancy Complications, Infectious | 17 | 2024 | 484 | 1.590 |
Why?
|
| Antibodies, Bacterial | 15 | 2019 | 404 | 1.490 |
Why?
|
| Infant, Newborn, Diseases | 6 | 2019 | 180 | 1.240 |
Why?
|
| Polysaccharides, Bacterial | 6 | 2016 | 70 | 1.050 |
Why?
|
| Carrier State | 4 | 2019 | 77 | 0.970 |
Why?
|
| Bacterial Capsules | 4 | 2019 | 41 | 0.880 |
Why?
|
| Vaccines, Conjugate | 9 | 2019 | 82 | 0.850 |
Why?
|
| Pregnancy | 24 | 2024 | 7523 | 0.810 |
Why?
|
| Lymphadenitis | 1 | 2022 | 26 | 0.790 |
Why?
|
| Eye | 1 | 2023 | 246 | 0.750 |
Why?
|
| Eye Diseases | 1 | 2023 | 138 | 0.750 |
Why?
|
| Streptococcus pyogenes | 1 | 2022 | 79 | 0.750 |
Why?
|
| Skin Diseases | 1 | 2022 | 135 | 0.710 |
Why?
|
| Vancomycin | 3 | 2013 | 236 | 0.650 |
Why?
|
| Infant, Newborn | 22 | 2021 | 8592 | 0.610 |
Why?
|
| Meningitis, Bacterial | 3 | 2021 | 98 | 0.580 |
Why?
|
| Infant | 17 | 2022 | 13161 | 0.580 |
Why?
|
| Humans | 66 | 2024 | 133932 | 0.530 |
Why?
|
| Female | 49 | 2024 | 71659 | 0.520 |
Why?
|
| Immunoglobulin G | 11 | 2019 | 823 | 0.500 |
Why?
|
| Vaccines | 1 | 2020 | 380 | 0.470 |
Why?
|
| Anti-Bacterial Agents | 8 | 2021 | 2520 | 0.460 |
Why?
|
| Simplexvirus | 1 | 2014 | 107 | 0.450 |
Why?
|
| Chorioamnionitis | 1 | 2014 | 45 | 0.450 |
Why?
|
| Herpes Simplex | 1 | 2014 | 57 | 0.450 |
Why?
|
| Haemophilus Infections | 1 | 2014 | 95 | 0.420 |
Why?
|
| Haemophilus influenzae | 1 | 2014 | 134 | 0.420 |
Why?
|
| Stillbirth | 1 | 2014 | 103 | 0.410 |
Why?
|
| Drug Monitoring | 1 | 2013 | 181 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 894 | 0.360 |
Why?
|
| Bacterial Infections | 2 | 2013 | 325 | 0.360 |
Why?
|
| Bacteremia | 5 | 2016 | 418 | 0.350 |
Why?
|
| Infant, Premature | 3 | 2014 | 859 | 0.350 |
Why?
|
| Physicians | 1 | 2018 | 630 | 0.350 |
Why?
|
| Bartonella | 1 | 2010 | 11 | 0.340 |
Why?
|
| Bartonella Infections | 1 | 2010 | 7 | 0.340 |
Why?
|
| Opportunistic Infections | 2 | 2018 | 79 | 0.340 |
Why?
|
| Retinitis | 1 | 2010 | 18 | 0.340 |
Why?
|
| Adult | 26 | 2024 | 31946 | 0.330 |
Why?
|
| United States | 12 | 2024 | 11683 | 0.330 |
Why?
|
| Orbital Diseases | 1 | 2010 | 94 | 0.320 |
Why?
|
| Mothers | 3 | 2021 | 369 | 0.320 |
Why?
|
| Serotyping | 4 | 2018 | 178 | 0.320 |
Why?
|
| Premature Birth | 1 | 2014 | 417 | 0.320 |
Why?
|
| Sinusitis | 1 | 2010 | 118 | 0.320 |
Why?
|
| Malaria | 1 | 2010 | 105 | 0.310 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2008 | 5 | 0.300 |
Why?
|
| Thyroglossal Cyst | 1 | 2008 | 5 | 0.300 |
Why?
|
| Meningococcal Infections | 1 | 2008 | 20 | 0.290 |
Why?
|
| Tetanus Toxoid | 3 | 2006 | 48 | 0.290 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 789 | 0.280 |
Why?
|
| Child | 17 | 2024 | 25739 | 0.280 |
Why?
|
| Brain Diseases | 1 | 2010 | 311 | 0.280 |
Why?
|
| Abscess | 1 | 2008 | 141 | 0.260 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2021 | 57 | 0.260 |
Why?
|
| Streptococcus | 1 | 2006 | 63 | 0.250 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 317 | 0.240 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 128 | 0.230 |
Why?
|
| Male | 23 | 2024 | 65882 | 0.230 |
Why?
|
| Familial Mediterranean Fever | 1 | 2004 | 4 | 0.230 |
Why?
|
| Diverticulitis | 1 | 2024 | 8 | 0.230 |
Why?
|
| Neutrophils | 2 | 2004 | 401 | 0.230 |
Why?
|
| Abdominal Abscess | 1 | 2024 | 27 | 0.230 |
Why?
|
| Cholecystitis, Acute | 1 | 2024 | 18 | 0.230 |
Why?
|
| Cholangitis | 1 | 2024 | 39 | 0.220 |
Why?
|
| Fever of Unknown Origin | 1 | 2004 | 45 | 0.220 |
Why?
|
| Blood Culture | 1 | 2024 | 34 | 0.220 |
Why?
|
| Vagus Nerve | 1 | 2004 | 47 | 0.220 |
Why?
|
| Infant, Premature, Diseases | 2 | 2004 | 255 | 0.220 |
Why?
|
| Texas | 4 | 2015 | 3689 | 0.210 |
Why?
|
| Young Adult | 8 | 2019 | 9887 | 0.210 |
Why?
|
| Adolescent | 13 | 2018 | 20536 | 0.210 |
Why?
|
| Salivary Gland Diseases | 1 | 2003 | 5 | 0.210 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 109 | 0.210 |
Why?
|
| Child, Preschool | 7 | 2022 | 14800 | 0.210 |
Why?
|
| Rhizobium | 1 | 2003 | 4 | 0.210 |
Why?
|
| Appendicitis | 1 | 2024 | 130 | 0.200 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 39 | 0.200 |
Why?
|
| Cellulitis | 1 | 2022 | 63 | 0.190 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2003 | 88 | 0.190 |
Why?
|
| Vaccination | 4 | 2019 | 1011 | 0.190 |
Why?
|
| Cronobacter sakazakii | 1 | 2021 | 4 | 0.190 |
Why?
|
| Surgical Wound Infection | 1 | 2004 | 276 | 0.190 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1197 | 0.190 |
Why?
|
| Phagocytosis | 5 | 2012 | 191 | 0.180 |
Why?
|
| Milk, Human | 1 | 2004 | 310 | 0.180 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 135 | 0.180 |
Why?
|
| Prevalence | 3 | 2018 | 2654 | 0.180 |
Why?
|
| Antibody Specificity | 4 | 2016 | 206 | 0.180 |
Why?
|
| India | 2 | 2018 | 238 | 0.170 |
Why?
|
| Rectum | 2 | 2018 | 113 | 0.170 |
Why?
|
| Infant Formula | 1 | 2021 | 100 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 214 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 866 | 0.160 |
Why?
|
| Risk Factors | 4 | 2022 | 11087 | 0.160 |
Why?
|
| Syndrome | 1 | 2022 | 1165 | 0.160 |
Why?
|
| Vagina | 2 | 2018 | 201 | 0.160 |
Why?
|
| Vaginosis, Bacterial | 1 | 2019 | 19 | 0.160 |
Why?
|
| Retrospective Studies | 8 | 2013 | 17481 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 287 | 0.150 |
Why?
|
| Obesity | 1 | 2011 | 2413 | 0.150 |
Why?
|
| Biopsy | 2 | 2014 | 1304 | 0.150 |
Why?
|
| Trichosporonosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 18 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 176 | 0.150 |
Why?
|
| Infectious Disease Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| HIV Infections | 1 | 2010 | 2067 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2021 | 13011 | 0.140 |
Why?
|
| Staphylococcal Infections | 3 | 2010 | 573 | 0.140 |
Why?
|
| Immunoglobulin M | 3 | 2007 | 224 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2013 | 376 | 0.130 |
Why?
|
| Molecular Typing | 1 | 2016 | 34 | 0.130 |
Why?
|
| Epilepsy | 1 | 2004 | 891 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 304 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1631 | 0.120 |
Why?
|
| Middle Aged | 6 | 2018 | 29394 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 833 | 0.120 |
Why?
|
| Genome, Bacterial | 1 | 2016 | 212 | 0.120 |
Why?
|
| Acyclovir | 1 | 2014 | 47 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 7204 | 0.110 |
Why?
|
| Umbilical Cord | 1 | 2014 | 59 | 0.110 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2014 | 15 | 0.110 |
Why?
|
| Whole Genome Sequencing | 1 | 2016 | 327 | 0.110 |
Why?
|
| Cordocentesis | 1 | 2013 | 10 | 0.110 |
Why?
|
| Immunoglobulin A | 2 | 2005 | 217 | 0.110 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2014 | 35 | 0.110 |
Why?
|
| Whooping Cough | 1 | 2014 | 60 | 0.110 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2013 | 35 | 0.110 |
Why?
|
| Antigens, Viral | 1 | 2014 | 440 | 0.100 |
Why?
|
| Blood Bactericidal Activity | 1 | 2012 | 17 | 0.100 |
Why?
|
| Opsonin Proteins | 1 | 2012 | 20 | 0.100 |
Why?
|
| Hearing Disorders | 1 | 2012 | 30 | 0.100 |
Why?
|
| United Kingdom | 1 | 2012 | 239 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1489 | 0.100 |
Why?
|
| Gestational Age | 2 | 2014 | 1217 | 0.100 |
Why?
|
| Immunization | 3 | 2014 | 315 | 0.090 |
Why?
|
| Device Removal | 2 | 2004 | 225 | 0.090 |
Why?
|
| Genotype | 1 | 2018 | 2807 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2013 | 166 | 0.090 |
Why?
|
| Acute Disease | 2 | 2024 | 1189 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 809 | 0.090 |
Why?
|
| Age of Onset | 2 | 2010 | 635 | 0.090 |
Why?
|
| Pallor | 1 | 2010 | 2 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2013 | 3640 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1761 | 0.090 |
Why?
|
| Half-Life | 1 | 2011 | 160 | 0.090 |
Why?
|
| Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2010 | 2 | 0.090 |
Why?
|
| Aged | 5 | 2016 | 21730 | 0.090 |
Why?
|
| Coma | 1 | 2010 | 57 | 0.090 |
Why?
|
| Organophosphonates | 1 | 2010 | 21 | 0.090 |
Why?
|
| Oxazines | 1 | 2010 | 26 | 0.080 |
Why?
|
| Placenta | 1 | 2014 | 535 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2024 | 3695 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2010 | 84 | 0.080 |
Why?
|
| Developing Countries | 1 | 2012 | 288 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2012 | 238 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2010 | 330 | 0.080 |
Why?
|
| Antimalarials | 1 | 2010 | 46 | 0.080 |
Why?
|
| Doxycycline | 1 | 2010 | 121 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2010 | 58 | 0.080 |
Why?
|
| Adenine | 1 | 2010 | 122 | 0.080 |
Why?
|
| Blood | 1 | 2010 | 105 | 0.080 |
Why?
|
| Rifampin | 1 | 2010 | 134 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 283 | 0.080 |
Why?
|
| Brain | 1 | 2021 | 3220 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 1909 | 0.080 |
Why?
|
| Microscopy | 1 | 2010 | 123 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2014 | 825 | 0.080 |
Why?
|
| Travel | 1 | 2010 | 124 | 0.080 |
Why?
|
| Neisseria meningitidis | 1 | 2008 | 20 | 0.070 |
Why?
|
| Cefotaxime | 1 | 2008 | 38 | 0.070 |
Why?
|
| Hematoma | 1 | 2009 | 94 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 229 | 0.070 |
Why?
|
| Pediatrics | 1 | 2018 | 1217 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 1887 | 0.070 |
Why?
|
| Genomics | 1 | 2016 | 1676 | 0.070 |
Why?
|
| Overweight | 1 | 2011 | 384 | 0.070 |
Why?
|
| Craniocerebral Trauma | 1 | 2009 | 142 | 0.070 |
Why?
|
| Aging | 2 | 2005 | 1302 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 3990 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2012 | 733 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 345 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1735 | 0.070 |
Why?
|
| Antibody Affinity | 1 | 2006 | 41 | 0.070 |
Why?
|
| Body Weight | 1 | 2011 | 1034 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 109 | 0.060 |
Why?
|
| Gentamicins | 2 | 2004 | 96 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2005 | 3739 | 0.060 |
Why?
|
| Seizures | 1 | 2010 | 889 | 0.060 |
Why?
|
| Colchicine | 1 | 2004 | 39 | 0.060 |
Why?
|
| Length of Stay | 1 | 2010 | 1383 | 0.060 |
Why?
|
| Soft Tissue Infections | 1 | 2005 | 91 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2009 | 1003 | 0.050 |
Why?
|
| Nafcillin | 1 | 2003 | 14 | 0.050 |
Why?
|
| Ticarcillin | 1 | 2003 | 8 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2003 | 35 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 828 | 0.050 |
Why?
|
| Pneumocystis | 1 | 2002 | 12 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2004 | 243 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2002 | 40 | 0.050 |
Why?
|
| Lung | 1 | 2010 | 1557 | 0.050 |
Why?
|
| Penicillins | 1 | 2003 | 155 | 0.050 |
Why?
|
| Prednisone | 1 | 2002 | 289 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 319 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6588 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2014 | 1667 | 0.040 |
Why?
|
| Sepsis | 1 | 2004 | 516 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 294 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2002 | 383 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 330 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2003 | 476 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 5505 | 0.040 |
Why?
|
| Voriconazole | 1 | 2018 | 35 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2018 | 36 | 0.040 |
Why?
|
| Echinocandins | 1 | 2018 | 44 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 93 | 0.040 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2019 | 114 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 2161 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1977 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 63 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 201 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2007 | 179 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 3072 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2018 | 309 | 0.030 |
Why?
|
| Virulence | 1 | 2016 | 279 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2009 | 322 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 571 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2016 | 452 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 498 | 0.030 |
Why?
|
| Foodborne Diseases | 1 | 2014 | 12 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 6664 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 55 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2014 | 123 | 0.030 |
Why?
|
| Triatoma | 1 | 2014 | 30 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 129 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 784 | 0.030 |
Why?
|
| Insect Vectors | 1 | 2014 | 114 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2014 | 278 | 0.030 |
Why?
|
| Hearing Tests | 1 | 2012 | 16 | 0.020 |
Why?
|
| Vision Screening | 1 | 2012 | 7 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2014 | 227 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 569 | 0.020 |
Why?
|
| Disease Notification | 1 | 2012 | 8 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2012 | 94 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2012 | 205 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 87 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 567 | 0.020 |
Why?
|
| Child Development | 1 | 2014 | 287 | 0.020 |
Why?
|
| Bacterial Proteins | 2 | 2007 | 930 | 0.020 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2009 | 28 | 0.020 |
Why?
|
| Ampicillin | 1 | 2009 | 57 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 183 | 0.020 |
Why?
|
| Drainage | 1 | 2009 | 265 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2007 | 119 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2940 | 0.020 |
Why?
|
| Coagulase | 1 | 2004 | 23 | 0.010 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2004 | 3 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 51 | 0.010 |
Why?
|
| Staphylococcus | 1 | 2004 | 68 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 3393 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2004 | 176 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 142 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2004 | 178 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 262 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 191 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2002 | 118 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2002 | 195 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2196 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 5173 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 36398 | 0.010 |
Why?
|